NasdaqGM:KOD 1 Year Share Price vs Fair Value Explore Kodiak Sciences's Fair Values from the Community and select ...

Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that ...

Barclays raised the firm’s price target on Kodiak Sciences (KOD) to $7 from $4 and keeps an Underweight rating on the shares. The company’s Q2 ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Fintel reports that on August 14, 2025, JP Morgan upgraded their outlook for Kodiak Sciences (NasdaqGM:KOD) from Underweight to Neutral. Analyst Price Forecast Suggests 14.21% Downside As of August 6, ...

--Kodiak Sciences Inc., today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R ...

PALO ALTO, Calif. , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing ...

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases.

PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative ...

PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ...

PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended ...

--Kodiak Sciences Inc., today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said ...